TRIPLE NEGATIVE BREAST NEOPLASMS

This early-stage study aimed to find a safe dose and understand how the body processes a new experimental drug called boserolimab. It involved 182 adults with advanced cancers, including lung and breast cancer, who had run out of standard treatment options. Researchers tested bos…

This study tested if a combination of olaparib and pembrolizumab works better than standard chemotherapy plus pembrolizumab for controlling advanced triple-negative breast cancer. It involved 462 people whose cancer had responded to initial treatment. The goal was to see which ap…

This trial tested whether adding a year of avelumab, an immunotherapy drug, after standard surgery and chemotherapy could help keep cancer from returning in patients with high-risk triple-negative breast cancer. It involved 474 patients who had already completed their main cancer…

This study tested a new two-drug combination for people with advanced triple-negative breast cancer that had spread and could not be removed by surgery. The main goals were to check the safety of the drugs together and see if they could shrink tumors. The trial involved 185 parti…

This large study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy, both before and after surgery, works better than chemotherapy alone for triple negative breast cancer. It involved 1,174 patients with locally advanced disease who hadn't receive…

This early-stage study tested a new drug, TAK-676, combined with an existing immunotherapy (pembrolizumab) after a short course of radiation. It involved 34 adults with advanced lung cancer, triple-negative breast cancer, or head and neck cancer that had stopped responding to sta…

This large, completed study tested whether adding a drug called atezolizumab to standard chemotherapy could help patients with a hard-to-treat, aggressive form of breast cancer that had returned or spread. It involved nearly 600 patients whose cancer had come back quickly after p…